Faculty
Dr. Lars Arendt-Nielsenis full professor in translational pain research, founder, and director of the international Center for Sensory-Motor Interaction (SMI), Aalborg University, Denmark. Founder and director of R&D at the clinical trial unit C4Pain. He has published more than 840 peer-reviewed journal papers on experimental and clinical assessment of pain with the focus on musculoskeletal pain.
Has delivered more than 240 keynote lectures and co-edited 4 IASP books. Has served on the IASP Council, as co-chair of the IASP Global Year Against Musculoskeletal Pain in 2010, co-chair for the IASP Global Year Against Joint Pain 2016, editor-in-chief for IASP Press and chair the IASP’s Special Interest Group on Musculoskeletal Pain.
Prof. Susan Bartlett, PhD is Associate Professor of Medicine at McGill University in Montreal, Canada and Adjunct Associate Professor at the Johns Hopkins School of Medicine in Baltimore, USA. A clinical psychologist and behavioral epidemiologist by training, Dr. Bartlett’s research focuses on behavioral and social consequences of living with rheumatic diseases and patient-centered approaches to research and care. Her research has been funded by the, National Institutes of Health, Canadian Institutes of Health, PCORI, the American College of Rheumatology, the Arthritis Foundation, and the Arthritis Society. She lives in Montreal with her husband and two daughters.
Dr. Francisco J. Blanco is a rheumatologist at the Hospital Universitario A Coruña (Spain), Scientific Director of the Research Biomedical Institute (INIBIC) and Associate Professor at the Faculty of Medicine of the University of Santiago de Compostela (Spain). He trained as a rheumatologist at the Hospital 12 de Octubre of Madrid (1989–1992). He has been a fellow researcher at the University of California, San Diego-La Jolla during 1993 and 1994, obtaining a PhD from the University of A Coruña in 1998. Dr. Blanco leads a research group that studies the cellular and molecular mechanisms of cartilage destruction and repair in osteoarthritis, as well as searches for useful Biomarkers for the diagnosis, prognosis and therapeutic response of Rheumatic Diseases. He was Secretary General of the Osteoarthritis Research Society International (OARSI) from 2013 to 2015 and was member of the Director Board of OARSI from 2009 to 2013. In addition, he is a member of the Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), belonging to the Red de Inflamación y Enfermedades Reumáticas (RIER) and he is director of the Nodo of A Coruña of the Red Nacional de Proteómica del Instituto de Salud Carlos III (Proteo-Red/ISCIII). Dr. Blanco leads, at the University of A Coruña, the «Catedra-Bioibérica» which studies the degradation and reconstruction of joint cartilage and, since 2013, he is the national coordinator for the Biology and Disease platform of the Human Proteomic Project. Dr. Blanco is member of the EULAR study group of OA.
Prof. Louis Bessette,
MD, FRCP(C), M.Sc. Rheumatologist, Centre Hospitalier Universitaire de Québec, Pavillon CHUL Assistant professor at Laval University.
Dr. Bessette completed his medical training in rheumatology at Laval University in 1993. From 1994 to 1996, he received a formation in clinical research at the Multipurpose Arthritis Center of the Brigham and Women’s hospital in Boston. During the same period, he completed a master degree in epidemiology at the Harvard School of Public Health. Louis Bessette is Co-Director for Quebec City CaMos, a Canadian epidemiologic study in osteoporosis. He is also the Program Officer for the Quebec Recognizing Osteoporosis and its Consequences (ROCQ) Program. This program evaluates the diagnostic and treatment rates of osteoporosis following fragility fractures in women, aged 50 years and over. He is director of the rheumatology training program at Laval University since 2008 and the chief of the division of rheumatology at the CHU de Quebec.
He is the author and co-author of 65 scientific manuscripts and 200 abstracts. His major research interests include rheumatoid arthritis, spondyloarthritis, osteoarthritis, osteoporosis, quality of life aspect of musculoskeletal diseases and pharmacoeconomic studies.
Prof. Gilles Boire
Professor, Department of Medicine, Université de Sherbrooke. Rheumatologist, Centre hospitalier universitaire de Sherbrooke
Clinical interests: adult and pediatric inflammatory joint diseases. Interdisciplinary collaboration
Research interests: prognostic signatures in recent-onset inflammatory polyarthritis, consisting of protein and genetic biomarkers and of psychosocial characteristics. 107 published papers; h index 24.
Supervised 19 graduate and postgraduate students, trained 17 rheumatology fellows. Actively involved at all levels in medical education, as well as in knowledge translation to patients, family physicians and specialists
Anca Catrina is adjunct professor and senior consultant at the Rheumatology Department at Karolinska Institute and University Hospital in Stockholm, Sweden, a EULAR center of excellence in rheumatology. She qualified from the University of Medicine in Bucharest, Romania and received a PhD degree in rheumatology at Karolinska Institute. She leads a mixed team of basic and clinical scientists performing translational research in the field of rheumatology with a special focus on rheumatoid arthritis. Her team focuses on understanding early articular and extra-articular immune events leading to disease in individuals at risk for developing rheumatoid arthritis.
Dr. Flavia Cicuttini is a clinical rheumatologist and epidemiologist in the School of Public Health and Preventive Medicine with a long history of research in the area of musculoskeletal health. A major focus of her work has been on improving the methods for assessing joints using new methods such as magnetic resonance imaging. This has enabled a greater understanding of the mechanisms of early joint disease and has enabled new approaches to the prevention and treatment of arthritis.
Prof. Bernard Combe is Professor of Rheumatology at Montpellier University, France, and Head of the Bone and Joint Department at Montpellier University Hospital.
He completed his medical education at Montpellier University and was subsequently awarded a research fellowship in clinical immunology at the University of Texas, San Antonio, USA.
Prof. Combe was elected member of the National Board of Universities (Rheumatology) from 1994–2000 and again from 2006, as well as being president from 2010–2013. He is an active member of numerous EULAR and ACR task forces. Prof. Combe is Editor-in-Chief of RMD Open (EULAR / BMJ journal) and of La Lettre du Rhumatologue. In addition, he is a member of the editorial boards of Annals of Rheumatic Diseases, Arthritis and Rheumatism and Joint Bone Spine. Prof. Combe has co-authored more than 315 articles published in international
peer-reviewed journals, and has been a coordinator or main investigator in 131 clinical trials.
Prof. Philip Conaghan MBBS PhD FRACP FRCP is Professor of Musculoskeletal Medicine at the University of Leeds and a Rheumatologist for the Leeds Teaching Hospitals NHS Trust. He is a Senior Investigator for the UK National Institute for Health Research (NIHR) and Deputy Director of the NIHR Leeds Musculoskeletal Biomedical Research Unit. His research spans translational studies through large clinical trials, with major interests in understanding pathogenesis and therapeutic response for common arthritides including osteoarthritis and rheumatoid arthritis. He is a senior executive member of the international outcomes group OMERACT. He was inaugural Chair of the EULAR Standing Committee on Musculoskeletal Imaging and is Past-President of the International Society for Musculoskeletal Imaging in Rheumatology. He is on a number of journal editorial boards, is co-editor of the most recent Oxford Textbook of Rheumatology and has authored over 400 publications as original research, reviews and book chapters.
Dr. Jordi Monfort Faure Graduated in Medicine at the Universitat Central de Barcelona, Specialty Registrar of Rheumatology, Parc de Salut Mar. Hospital del Mar Barcelona, Master in Biomedical Sciences, Université de Montréal, Profeciency University of McGill. Montreal, Master in hospital management International University of Catalonia, PhD, Universitat Autonòma de Barcelona 2010-2013
He is currently an Associated Professor of Rheumatology Universitat Autònoma de Barcelona
Prof. Steffen Gay has graduated from the Medical School at the University in Leipzig in 1972. After medical and research training in Germany, he has been holding office from 1976-1996 at the Department of Medicine at the University of Alabama in Birmingham AL, and served there as Professor of Medicine from 1984 -1996. Since 1996 he is Professor of Experimental Rheumatology at the University Hospital of Zurich, Switzerland. The Center has been recognized as a EULAR Center of Excellence in Rheumatology from 2005-2015.
The Center of Experimental Rheumatology has been part of the EC supported EURO-RA Marie Curie Actions Research Training Networks (RTNs), such as EURO-RA and was part of the EC-FP6 supported AUTOCURE project (2006-11) and the EC FP7 MASTERSWITCH project (2008-2013).Now the Center is supported by the Institute of Arthritis Research (2010-2016), the EC IMI BTCure (2011-2016), the EC Marie Curie OsteoImmune (2012-2016) and the EC EuroTEAM (2012-2016).
Steffen Gay has published largely related to the molecular and cellular basis of rheumatic diseases, including 64 book chapters and over 380 peer-reviewed scientific papers. He is among the most cited scientists in Clinical Medicine (ISI) with over 19,000 citations and an h-index of 77. Prof. Gay is an Honorary Member of the American Association of Physicians (AAP) and the Alpha Omega Alpha Honor Medical Society. He became the Spinoza Professor for 2002 at University of Amsterdam and a member of the German National Academy of Sciences Leopoldina in 2004. In 2008 he received the Kussmaul-Medal from the German Society of Rheumatology and became Honorary Member of EULAR in 2011.
In 2014 he was appointed by the European Commission (EC) to participate in the strategic work of the Scientific Panel for Health (SPH). Steffen Gay is a principal in the SDG,LLC which assists FDA regulated industry in the development of regulatory strategies.
Prof. Juan J Gómez-Reino is based at the Fundacio Ramon Dominguez, Hospital Clínico Universitario at Santiago de Compostela, Santiago, Spain. He was formerly Head of the Deparment of Rheumatologyat the institution , and Chief of the Department of Research and Section of Rheumatology at Hospital Doce de Octubre, Madrid, Spain. Professor Gómez-Reino’s
focus of his clinical practice being rheumatoid arthritis, spondylarthrophathies and connective tissue diseases. His personal research interest is in chronic inflammatory arthropathies and his experimental research focus is the genetics of complex diseases, the effect of adopokines on chondrocyte function, and models of arthritis in gene‘knockout’ mice. Professor Gómez-Reino has authored or co-authored original articles and papers on topics including rheumatoid arthritis, spondyloarthritis and other Rheumatology-specific disorders.
Dr. Antonio Gonzalez directs research focused in the application of genetics to the rheumatic diseases in the Health Research Institute-University Hospital of Santiago de Compostela (Spain) since 2001. His areas of inquire are the search of treatment targets, groups of patients with homogeneous disease mechanisms, and biomarkers of response to treatment. In the osteoarthritis field, his work has contributed to define the genetic component of the disease, including the identification of susceptibility loci, initiate epigenetic studies and examine the interaction with aging.
Prof. Boulos Haraoui, MD FRCPC is an Associate Professor of Medicine at the Université de Montréal and head of the Clinical Research Unit in Rheumatology at the Centre hospitalier de l’Université de Montréal (CHUM) and the Institut de rhumatologie de Montréal.
Dr Haraoui received his medical degree from St. Joseph University in Beirut, Lebanon. Following his post graduate training in Internal Medicine and Rheumatology at the University of Montreal, he completed a research Fellowship at the Arthritis Branch of the National Institutes of Health in Bethesda, Maryland.
He is a founding member and vice-chairman of the Canadian Rheumatology Research Consortium (CRRC). He also chairs the Canadian Initiative in Outcomes in Rheumatology Care (CIORA), the research granting committee of the CRA
Doctor Haraoui is a Past-Chairman of the Scientific Committee of the Canadian Rheumatology Association.
He was an examiner for the Royal College of Physicians and Surgeons of Canada and a member of the Subspecialty Committee on Rheumatology of the RCPSC. He is also a past chairman of the Laurentian Conference of Rheumatology
Doctor Haraoui serves on several provincial, national and international educational and advisory committees, especially on issues pertaining to the diagnosis and management of rheumatoid arthritis.
Dr. Graeme Jones attended Sydney University graduating with first class honours in Medicine in 1985. He then did training in Internal Medicine and Rheumatology in Sydney and Newcastle. He became a fellow of the Royal Australasian College of Physicians in 1991. While at Newcastle he also did a Masters degree in Clinical Epidemiology. He then moved to the Garvan Institute in Sydney where he completed a doctorate in Osteoporosis Epidemiology in 1994. He is also a fellow of the Australian faculty of Public Health Medicine. Since 1995 he has been in Hobart, Tasmania where he combines clinical practice and research. He is currently Professor of Rheumatology and Epidemiology and Head of the Musculoskeletal Unit at the Menzies Research Institute as well as Head of the Department of Rheumatology at Royal Hobart Hospital. An NHMRC Practitioner Fellowship funds his position. He is also the current Medical Director of the Arthritis Foundation of Australia. He has received grants from competitive and non-competitive sources totalling over $16 million dollars and has published >250 articles primarily on the epidemiology of osteoporosis and osteoarthritis. In more recent years he has concentrated on both industry sponsored and investigator initiated clinical trials. He has received awards and given numerous oral presentations at the annual scientific meetings of the American Society for Bone and Mineral Research, the American College of Rheumatology, OARSI and EULAR. His current research interests are the development of peak bone mass and fracture aetiology in children, genetic and environmental risk factors for osteoarthritis, health promotion, the role of environmental factors such as diet and physical activity in osteoporosis and fractures in the elderly, clinical trials and meta-analysis.
Dr. Nancy Lane is currently the Endowed Professor of Medicine, Rheumatology and Aging, and Director of the Center for Musculoskeletal Health at the University of California at Davis School of Medicine. She is an internationally known expert on the epidemiology and treatment of musculoskeletal diseases including osteoarthritis and osteoporosis and has published over 300 peer reviewed journal articles Dr. Lane and her research team have performed seminal translational studies on novel agents to reduce pain and restore joint tissue in osteoarthritis and restore bone tissue in patients with severe glucocorticoid induced osteoporosis.
Dr. Burkhard F. Leeb received his medical degree from the University of Vienna in 1981.
Subsequently he spent his residency and training in internal medicine as well as
in rheumatology at Lainz Hospital, Vienna, Austria.
From 1990 to 1999 he served as a consultant at the 2nd Dept. of Medicine, Center for
Rheumatology, at the respective hospital. He received his specialization in rheumatology in 1994.
1999 he was appointed director of the newly established center for rheumatology, Lower Austria,
at Stockerau Hospital and subsequently director of the 2nd department of medicine.
Aside this occupation Dr. Leeb had the honor to serve as a member and also as
co-convenor of several EULAR task-forces, amongst them the ones for osteoarthritis,
gout and polymyalgia rheumatica.
Up to date Dr. Leeb has published more than 150 articles in peer reviewed journals,
as well as in books. His main scientific interests are arthritides, polymyalgia rheumatica,
as well as osteoarthritis and above all the problems along with disease activity assessment. In 2010 Dr. Leeb earned his postdoctoral lecturer qualifiction from the Medical University of Graz. From 2008 until the end of 2010, Dr. Leeb had the honor to serve as president of the Austrian society for rheumatology and rehabilitation.
Dr. Emmanuel Maheu Medical Doctor, Consultant Rheumatologist at St-Antoine Hospital, and private practice.
Involved in clinical research on: Hand osteoarthritis (clinical and imaging issues ; clinical trials guidelines) ; clinical trials in OA ; radiographic assessment methods in hip/knee OA ; intra-articular therapy, hyaluronic acids.
Member of the OARSI since its foundation; Member of the French Society of Rheumatology Board until 2014.
Chair of the Working group Association Geriatry and Rheumatology (AGRHUM).
Chair of the OARSI subgroup on the recommendations for hand OA clinical trials
Author of more than 60 peer-reviewed publications.
Reviewer for several Rheumatology Journals: Annals of the Rheumatic Diseases, Arthritis and Rheumatology, Arthritis Care and Research, Osteoarthritis and Cartilage, The Journal of Rheumatology, Rheumatology.
Member of the Editorial Board of Osteoarthritis and Cartilage
Alejandro Olive Marques, Spain
Dr. Alejandro Olivé was born in Barcelona in 1957. He studied Medicine in the Universidad Autonoma de Barcelona. He made his residency program at Hospital de la Esperanza at Barcelona Then he moved to the UK where he was Clinical Research Fellow at the Royal National Hospital for Rheumatic Diseases (Bath). He read his Thesis in 1990 : Felty´s syndrome : ”Lymphocyte phenotypes”. Currently he is Chief Rheumatholoy Service at Hospital Universitari Germans Trias i Pujol (Badalona). He is specialized in CTD , Adult Onset Still´ s Disease and Inflammatory arthropathies.
Johanne Martel-Pelletier, Canada
Prof. JOHANNE MARTEL-PELLETIER, Ph.D. is Professor of Medicine in the Department of Medicine and Accredited Member of the Department of Pharmacology at the University of Montreal. In 1981, she co-founded with Professor Jean-Pierre Pelletier, the Osteoarthritis Research Unit at the University of Montreal Hospital Centre, which today is world renowned for its research in the field. In 2000, they initiated a University Chair in Osteoarthritis at the University of Montreal and have been appointed titular heads of this Chair.Her research interests lie in the mechanisms involved in the etiology of osteoarthritis, such as joint tissue catabolism and cartilage repair, the molecular and biochemical mechanisms involved during the osteoarthritis process of certain proteases, pro- and anti-inflammatory factors, and growth factors in humans and targeting new therapeutic strategies for the treatment of osteoarthritis. In addition, she is involved in developing systems using magnetic resonance imaging technology for the automatic quantification of structural tissue changes in the human knee and hip.She is an active member of several editorial boards and committees and is a highly respected reviewer for numerous rheumatology and connective tissue journals and governmental and private research funding agencies at national and international levels. She has authored more than 410 publications including journal articles, reviews and book chapters and over 730 abstracts, as well as being guest editor of several journals and editor of four books. In addition, she has been an invited guest speaker at numerous national and international meetings and conferences. She is recipient of several distinguished scientific awards honouring her excellence and outstanding achievements in osteoarthritis research.
Dr. Jason McDougall was born in South Shields and educated in Glasgow. He received his PhD in Joint Physiology from the University of Glasgow and subsequently undertook postdoctoral training in Canada, Germany and Spain. Dr. McDougall was awarded postdoctoral fellowships from the Alberta Heritage Foundation for Medical Research (AHFMR), the Medical Research Council of Canada and was the recipient of the Ernst & Young Joint Injury & Arthritis Research Fellowship. In 2001 he joined the Faculty of Medicine at the University of Calgary where he held an AHFMR Senior Scholarship as well as an Arthritis Society Investigator award. He is currently a Professor in the Departments of Pharmacology and Anaesthesia at Dalhousie University.Dr. McDougall’s research focuses on the neurobiology of pain and how the nervous system can cause arthritis. Dr. McDougall’s lab uses electrophysiological and behavioural techniques to assess joint pain as well as employing intravital microscopy to assess leukocyte trafficking, and laser speckle imaging to assess joint blood flow. His research is currently examining the role of cannabinoids, proteinases and opioids in arthritis pain and inflammation. His research goal is to identify novel drug targets and discover new treatments which will help alleviate chronic pain and resolve joint inflammation. He receives project funding from CIHR, and The Nova Scotia Health Research Foundation. He has been a pain consultant on collaborative projects with Antibe Pharmaceuticals (Canada), AstraZeneca (UK), Eli Lilly & Company (USA) and Pfizer (UK). He also recently won the Garrison “Home Brew-Off” competition for his German Hefeweizen Beer.
Dr. Alberto Migliore served in the San Pietro Fatebenefratelli Hospital in Rome since 1990. Where he is currently Director of UOS of Rheumatology in the Department of Medicine.
Since 2005 is the Founder and President of the “National Association for Intra-articular therapy with Hip Guide Ecografica ANTIAGE- NPO”. It ‘the first National Association for the ultrasound treatment of rheumatic interesting hip in the world. This association also analyzes data regarding the infiltration of hip ultrasound guided from the various centers located throughout the national territory. He is Professor of Rheumatology at the nursing degree program of the Faculty of Medicine and Psychology. “Sapienza” since 2007 and a Professor of Rheumatology at the Degree in Health Professions in Nursing based INMI Spallanzani Faculty of Medicine and Psychology – AO Sant ‘Andrea in Rome since 2011. From 07.12.07 took over the role of Advisory Editor of the journal “Archives of Orthopaedic and Trauma Surgery”
Since November of 2009 ‘Editor in chief “of the magazine’ Topics of Therapy Intra-Articular ‘published by Verduci Publisher and sent to 4500 among orthopedic specialists, radiologists, physiatrists, rheumatologists and sports doctors.
Dr. Ingrid Moller
Director and consultant in Rheumatology and musculoskeletal sonography at the Institut Poal de Reumatología, Barcelona 1997
Assistant professor of anatomy, University of Barcelona
Organizer of the SONOANATOMY Workshops under the scientific endorsement of EULAR (2008-2013)
Faculty of:
The Sonoanatomy MASTER Universidad de Barcelona ( from 2011)
he Ultrasound School of the Spanish Society of Rheumatology from 2002
The EULAR courses of Ultrasound from 2006
Dr Christelle Nguyen, MD, PhD, is Assistant Professor of Physical Medicine and Rehabilitation (PMR) at Paris Descartes University. She has joined Professor François Rannou group (INSERM UMR-S 1124, Faculté des Sciences Fondamendales et Biomédicales, Sorbonne Paris Cité University) in 2014, after a 2-year Visiting Academic position at the Institute For Molecular Bioscience, University of Queensland, Australia. She is also consultant in the Department of PMR at Cochin Hospital (Head: Professor Serge Poiraudeau). She is currently leading translational research projects aiming: 1/ to better understand molecular mechanisms involved in intervertebral disc and articular cartilage diseases using original animal models, and 2/ to assess the efficacy and safety of non-pharmacological interventions in musculo-skeletal disorders including osteoarthritis and intervertebral disc diseases.
Jean-Pierre PELLETIER, MD, CSPQ, FRCP(C)Accredited member, Department of Pharmacology, Faculty of Medicine
Professor, Department of MedicineHead, Chair in Osteoarthritis, Université de Montréal
Head, Arthritis Centre, Université de Montréal
Head, Arthritis Division, Université de Montréal Hospital Centre (CHUM)
Director, Osteoarthritis Research Unit
University of Montreal Hospital Research Centre (CRCHUM)
Notre-Dame Hospital
1560 Sherbrooke Street East
Montreal, Quebec, H2L 4M1 CanadaTél. : 514 890-8000, poste 26666
Téléc. : 514 412-7582TrainingMedical degree, University of Montreal (1974)
Internal medicine FRCP(C) – CSPQ (1978)
Rheumatology (1980)
FACP (1980)
FLEX (1980)
Research fellow in rheumatology (1979-1981), Department of Medicine, University of Miami, Miami, Florida
Areas of ResearchPathophysiology and molecular mechanisms of human and experimental osteoarthritis
Pro-inflammatory cytokines and receptors
Proteolytic enzymes and inhibitors
Intracellular signaling pathways (i.e. MAP kinases) and transcription factors
Imaging (MRI) of osteoarthritis structural changes
Development of new therapeutics (DMOADs) for osteoarthritis
Techniques usedMolecular and cellular biology
Biochemistry
Immuhistology
Pharmacology
Animal models of osteoarthritis
Joint imaging
Clinical research
Laboratory personnelResearchers, research assistants, technicians, students: MSc, PhD, post-doctorate.
PublicationsWildi, L.M., Raynauld, J-P., Martel-Pelletier, J., Beaulieu, A., Bessette, L., Morin, F., Abram, F., Dorais, M., Pelletier, J-P. : Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee OA patients starting as early as 6 months after initiation of therapy : a randomized, double-blind, placebo controlled pilot study using MRI. Ann. Rheum. Dis. 70 :982-989, 2011.
Pelletier, J-P., Troncy, É., Bertaim, T., Thibaud, D., Goulet, A-C., Abram, F., Caron, J., Boileau, C., d’Anjou, M-A., Moreau, M., Lussier, B., Martel-Pelletier, J : Treatment with tiludronic acid helps reduce the development of experimental OA lesions in dogs with ACL transection followed by reconstructive surgery : A 1-year study with quantitative MRI. J. Rheumatol. 38:118-128, 2011.
Raynauld, J-P., Martel-Pelletier, J., Beaulieu, A., Bessette, L., Morin, F., Choquette, D., Haraoui, B., Abram, F., Pelletier, J-P. : An open-label 12-month pilot study evaluating by magnetic resonance imaging the potential for a disease modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis. Semin. Arthritis Rheum. 40 :185-192, 2010.
Pelletier, J-P., Raynauld, J-P., Caron, J., Mineau, F., Abram, F., Dorais, M., Haraoui, B., Choquette, D., Martel-Pelletier, J. : Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann. Rheum. Dis. 69 :2095-2101, 2010.
Raynauld, J-P., Martel-Pelletier, J., Bias, P., Laufer, S., Haraoui, B., Choquette, D., Beaulieau, A.D., Abram, F., Dorais, M., Vignon, E., Pelletier, J-P., and the Canadian Licofelone Study Group: Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: A first multi-centre clinical trial using quantitative MRI. Ann. Rheum. Dis. 68:938-947, 2009.
Dr. Charles G. Peterfy
EMPLOYMENT:
2009 – present Founder & Chief Executive Officer Spire Sciences, LLC
Spire Sciences provides centralized medical image analysis for clinical trials to the pharmaceutical, biotechnology and medical devices industries.
1998 – 2009 Co-founder, Chief Medical Officer & Executive Vice President Synarc, Inc.
Synarc (currently BioClinica, Inc.) provides centralized medical image analysis,
biochemical marker assay and subject recruitment facilities for clinical trials to
the pharmaceutical, biotechnology and medical devices industries.
1993-2000 Assistant Professor, Department of Radiology, University of California San Francisco School of Medicine
San Francisco, CA.
1995-1998 Medical Director of Arthritis and MRI Research Osteoporosis and Arthritis Research Group University of California San Francisco School of Medicine San Francisco, CA
1991-1998 Attending Radiologist,Department of Radiology, University of California San Francisco Medical Center
San Francisco, CA
OTHER AFFILIATIONS:
2011 – present Intersocietal Commission for the Accreditation of Magnetic Resonance Laboratories (ICAMRL) (Board of Directors) ICAMRL is a division of the Intersocietal Accreditation Commission (IAC), a non-profit organization aimed at ensuring high-quality patient care through accreditation of diagnostic MRI facilities.
2009 – present International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) (Co-founder, Board of Directors)
ISEMIR is a non-profit organization aimed at advancing research and education in musculoskeletal imaging in Rheumatology.
EDUCATION:
Postgraduate Clinical Fellowship:
Musculoskeletal Imaging: University of California, San Francisco, CA Concentration in bone, joint, and spine MRI. 1992
Radiology Residency:
McGill University, Montreal, Quebec, Canada 1991 Internship (mixed: Surgery & Medicine):
McGill University, Montreal, Quebec, Canada 1986 Graduate Ph.D. (Pharmacology & Therapeutics)
McGill University, Montreal, Quebec, Canada 1989 Medical M.D. C.M.
McGill University, Montreal, Quebec, Canada 1985 Undergraduate B.Sc. (Human Anatomy)
McGill University, Montreal, Quebec, Canada 1979
Theodore Pincus is Professor of Medicine at Rush University in Chicago, having served on faculties at Cornell, Stanford, University of Pennsylvania, Vanderbilt, and NYU. His early laboratory research included a radioimmunoassay for DNA antibodies as a test for systemic lupus erythematosus, and genes that control experimental retrovirus infection. In 1982, he recognized severe functional declines and premature death in rheumatoid arthritis (RA), predicted most significantly by patient physical function scores and by low socioeconomic status. He documented that early methotrexate and 3 mg prednisone improved RA outcomes considerably. He has developed patient MDHAQ/RAPID3 and physician RheuMetric to improve workflow in clinical settings and record clinical information as quantitative, standard “scientific” data, beyond narrative descriptions. MDHAQ scores indicate that disease burden at this time in routine rheumatology care is greater in patients with osteoarthritis than in patients with RA.
Dr. Janet Pope is a Professor of Medicine in the Division of Rheumatology and also Epidemiology and Biostatistics at the University of Western Ontario (UWO), Schulich School of Medicine, London, Ontario, Canada. She is the Division Head in Rheumatology at St. Joseph’s Health Centre, London. She obtained her MD, and Fellowship in Internal Medicine at UWO and a Fellowship in Rheumatology and Masters of Public Health were acquired at Boston University. She then completed a Canadian Arthritis Society Research Fellowship in Scleroderma. She is a founding member in the Canadian Scleroderma Research Group (CSRG) and CaNIOS (Canadian Network for Improved Outcomes in SLE). She is a member of the Scleroderma Clinical Trials Consortium. She chairs both the Canadian Rheumatology Association Clinical and Research Summer Studentships. She is on the Scientific Advisory Committee for the CATCH cohort (Canadian Early Arthritis Cohort) and the OBRI (Ontario Biologics Research Initiative). She is on the Editorial Boards of Arthritis & Rheumatology, Journal of Rheumatology, Arthritis Care Research and Nature Reviews Rheumatology. Her research includes epidemiologic studies in scleroderma, SLE and RA, including outcome measurements, clinical trials and disease manifestations. She has published over 360 peer-reviewed articles, 15 chapters, 450 abstracts and several Cochrane meta-analysis reviews. Mentoring of students and trainees numbers more than 50. She was awarded the Lupus Hope Award. She has received the Distinguished Investigator Award from the Canadian Rheumatology Association, Rheumatologist of the Year from the Ontario Rheumatology Association, Department of Medicine Research Achievement Award, and the Dean’s Award of Excellence in Research.
Dr. Jean-Pierre Raynauld obtained his medical degree at the University of Montreal (Montreal, Quebec, Canada) in 1983 and was appointed at the Department of Medicine at the University of Montreal in 1996. He completed his training in Clinical Rheumatology at the University of Montreal in 1989 and a Post-Doctoral Fellowship in Clinical Epidemiology, in the Division of Immunology and Rheumatology, at Stanford University in California, USA from 1990 to 1993. He is a Fellow in Internal Medicine and in Rheumatology of the Royal College of Physicians of Canada and is certified by the American Board of Internal Medicine and Rheumatology.Doctor Raynauld is an expert in the field of clinical research in osteoarthritis. He is Head of the Osteoarthritis Clinical Research Unit at the Montreal Rheumatology Institute affiliated with the University of Montreal Hospital Centre (CHUM). He was formerly vice-president of the Royal College of Physician Examination Board (rheumatology) and sits as President of the Canadian Laurentian Conference of Rheumatology. He was recently member of the Editorial Board of the Osteoarthritis and Cartilage journal.Doctor Raynauld’s research interests focus on the evaluation of the progression of osteoarthritis using magnetic resonance imaging (MRI). He is also interested in evaluating intra-articular approaches to the treatment of osteoarthritis. He has participated as principal investigator or co-investigator in several studies addressing clinical outcomes using intra-articular viscosupplements and corticosteroids, as well as having conducted studies using MRI technology to evaluate oral medications such as bisphosphonates, strontium ralenate, chondroitin sulfate, and other inhibitors of cartilage degradation in patients with knee osteoarthritis. He has published more than 75 original articles related to osteoarthritis and has presented at numerous meetings in North America.
Prof. François Rannou is Qualified in rheumatology and physical medicine. My clinical domain of expertise is devoted to osteoarthritis and spine diseases. In our research team, we study the effect of mechanical stress on articular chondrocytes and intervertebral disc cells. In clinical research, we are mostly interested in the assessment of non pharmacological treatments in rheumatic diseases.
I co-lead the scientific committee of the French society of rehabilitation (SOFMER) and assume the role of treasurer of the osteoarthritis research society international (OARSI).
Frédéric Sailhan, France
Lee S. Simon, MD, FACP, FACR
Dr. Simon is a Rheumatologist and has been the Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products (DAAODP) (2001-2003), within the Center for Drug Evaluation and Research (CDER), FDA. He has been the recipient of several Quality Performance Awards and a Faculty Recognition Award from the FDA. He has served on and has been the Acting Chair of the Arthritis Advisory Committee of the DAAODP (1993-2001). He has also served on the advisory committees for the Division of Over the Counter Drugs (1996), Center for Devices (1995), and for the Division of Hematologic and Gastroenterologic Drug Products (1996). He has also served as a consultant for DDMAC (1993), the American Hospital Formulary (1990) and AMA Drug Products (1990). He is presently a Principal in SDG LLC, a consulting firm helping companies to create successful drug development programs through good designs and using insightful regulatory strategy (2004-).He has been a clinical Rheumatologist for 25 years. He is a fellow of the American College of Physicians (1991) and the American College of Rheumatology (1986). Dr. Simon has had extensive experience in drug development in the US, and has served on consulting advisory boards for many different companies. This experience includes drugs and other therapeutics used for pain, anti-inflammatory effects, alteration of bone turnover, as well as modifying inflammatory disease states. He was a National Institutes of Health (NIH) funded investigator for 12 years working at the “wet bench” developing methodologies for in vitro measures approximating collagen turnover including the development of a commercial assay for measuring the carboxy-terminal portion of type I procollagen as a marker of new bone synthesis (1981-1993).
He has served for two terms on the Board of Directors of the American College of Rheumatology (ACR) (1991-1993, 1994-1997), served as the Chair of Education for the ACR and on the committee of the National Arthritis Foundation. He has served as the Scientific Abstract Selection Chair of the Annual Meeting of the ACR (2002). He has been awarded the 2003 Distinguished Service Award of the ACR and has been awarded the 2003 Scientific Leadership Award of the Lupus Research Institute. He served on the Steering Committee of IMPAACT, a group developing recommendations for the design and implementation of clinical trials investigating pain. He is on the Steering Committee and was Co-chair of the 2004 and 2012 OMERACT (Outcome Measures in Rheumatology) Biannual Meeting. OMERACT is a constituent group of the World Health Organization (WHO) through the International League of Associations of Rheumatology (ILAR). He served on the Steering Committee of the NIH Osteoarthritis Initiative (2001-2003). Dr. Simon has served as Chair of the biannual “Innovative Therapies in “Autoimmune Disease” conference sponsored by the ACR, FDA, NIH, and the Arthritis Foundation (2001-2005).
He has been on the editorial board of multiple journals and has authored more than 110 original publications, review articles and chapters, and has served as a co-editor of 4 books. He was Co-chair of the American Pain Society Guideline on the Treatment of Chronic Pain in Chronic Arthritis (1999-2001). He has presented on topics related to drug development, Rheumatology, the assessment and treatment of pain and bone disease. He served on the Scientific Advisory Committee of the National Osteoporosis Foundation, has been the Vice Chair of Medical Affairs of the Arthritis Foundation, Massachusetts Chapter as well as serving on its Board of Trustees (1992-2001). He was an Associate Professor of Medicine at Harvard Medical School (1995-2003) where he had been full time faculty since 1981, an Associate Chief of Medicine, Beth Israel Deaconess Medical Center (BIDMC) (1999-2001), Director of the Core Medicine Clerkship (1986-2000), Director of Clinical Rheumatology Research (1995-2001), Director of Graduate Medical Education at the BIDMC and the Deaconess Hospital (1989-2001), and Chair of Rehabilitation Services at the Deaconess Hospital (1986-1995), Harvard Medical School before joining the FDA. He served as a voluntary faculty member at Harvard and the BIDMC from 2004-2009 at which time he left to pursue a full time consulting practice in drug development and regulatory strategies.
Dr. Eric Troncy graduated from the National Veterinary School of Lyon (France, 1992) and went on to complete a residency in Veterinary Anaesthesia and Analgesia (1998, Université de Montréal), and obtained a PhD in Biomedical sciences (Pharmacology and applications of inhaled nitric oxide) at the Université de Montréal (Quebec, 1999).
Eric is an internationally recognized member of the scientific community for his work in animal pain, its evaluation (pain metrology) and management. He was received numerous awards, including: “Veterinarian of the Year” (France, 2001), Knight of the Ordre du Mérite Agricole of the French Republic (2009) for his work in animal pain management, “Researcher of the year 2010” and “Excellence in research 2013” by the Faculty of Veterinary Medicine (Université de Montréal), and Best 2013 Industry – University Partnership of the year in Quebec by ADRIQ and NSERC. His work is supported at international (Morris Animal Foundation, ERA-Can+), national (NSERC, CIHR and CFI) and provincial (FRQ-NT, FRQ-S) levels.
He has supervised 18 MSc and 11 PhD students over the last 6 years, and has authored 126 research publications, 88 continuing education publications, 138 guest presentations and 234 scientific abstracts. He is the current Director of the Research Group in Animal Pharmacology of Quebec (GREPAQ) at the Faculty of veterinary medicine (FVM) of the Université de Montréal. Most recently, his work has focused on pain mechanisms and functional restriction in naturally occurring and experimental osteoarthritis in dogs and cats, as well as in rats.
Ana M Valdes received her M.A. and Ph.D. from the University of California at Berkeley where she specialized in Genetic Epidemiology. A Reader and Associated Professor at the University of Nottingham. She has co-authored over 180 scientific publications and her work focuses on deciphering the molecular mechanisms using metabolomics and genetics related to age-related phenotypes and to diseases including osteoarthritis and gout.
David Walsh, UK
Gertjan Wolbink, Netherlands
Diane Van der Woude, Netherlands
Dr. Diane van der Woude is a staff rheumatologist at the Leiden University Medical Center, where she is head of the outpatient clinic. Her research interests are: autoantibodies, especially anti-citrullinated protein antibodies (ACPA), and risk factors for rheumatoid arthritis (RA), including genetic risk factors such as the human leukocyte antigen (HLA) alleles, on which she has published numerous articles. She is a member of the editorial board of Rheumatology (Oxford) and co-chair of the EULAR Study Group for Risk Factors for RA